RPTX — Repare Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $61.33m
- -$91.46m
- $53.48m
- 49
- 60
- 32
- 44
Annual cashflow statement for Repare Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -53.4 | -107 | -29 | -93.8 | -84.7 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 4.01 | 14.9 | 19.4 | 19.9 | 20.4 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 43.7 | 7 | 4.41 | -55.2 | -14.1 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -6.08 | -85.8 | 0.322 | -127 | -76.4 |
| Capital Expenditures | -2.24 | -1.69 | -0.602 | -1.94 | 0 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -7.53 | 0.014 | -175 | 80 | 49.5 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -9.76 | -1.68 | -176 | 78 | 49.5 |
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 248 | 95.6 | 0.88 | 0.842 | 0.542 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 231 | 8.03 | -175 | -48.3 | -26.6 |